Engineered CH2 domains (nanoantibodies).

Area of Science:

• Biotechnology
• Immunology
• Protein Engineering

Background:

• Therapeutic antibodies, typically IgG1 (150 kDa), face challenges with tissue penetration and binding to specific epitopes.
• Smaller molecular formats are needed to overcome limitations of large antibodies in applications like solid tumor targeting and binding to certain viral glycoproteins.

Purpose of the Study:

• To introduce a novel scaffold based on the immunoglobulin (Ig) constant CH2 domain for developing smaller, stable antibody-based therapeutics.
• To propose the term "nanoantibodies" (nAbs) for engineered CH2 domains functioning as antigen binders.

Main Methods:

• Proposing the use of the immunoglobulin CH2 domain (or CH3 for IgE/IgM) as a stable, monomeric scaffold.
• Engineering CH2 domains for enhanced stability and antigen-binding capabilities.
• Utilizing these engineered domains to construct libraries for diverse antigen binders.

Main Results:

• The CH2 domain is identified as a stable, independently folded antibody domain suitable for engineering.
• Engineered CH2 domains can be developed into nanoantibodies (nAbs) with antigen-binding sites.
• These nAbs have the potential to retain or confer effector functions and offer improved stability.

Conclusions:

• The immunoglobulin CH2 domain serves as a promising scaffold for novel nanoantibodies (nAbs).
• Nanoantibodies offer a smaller, potentially more effective alternative to conventional antibodies for therapeutic applications.
• This approach addresses key limitations of large antibody formats in drug delivery and targeting.